论文部分内容阅读
目的探讨放射性核素二氯化锶(89SrCl2)及89SrCl2联合唑来膦酸治疗转移性骨肿瘤的临床效果。方法采用随机方法将43例转移性骨肿瘤患者分为两组,单纯采用89SrCl2治疗组21例,89SrCl2与唑来膦酸联合治疗组22例。观察治疗后骨痛缓解疗效、转移病灶疗效、生活质量的情况及血液毒性反应。采用SPSS 14.0统计软件对数据进行χ2检验。结果单纯89SrCl2治疗组,治疗后疼痛缓解总有效率为71.4%(15/21),病灶治疗有效率为33.3%(7/21),全身状况KPS评分提高率57.1%(12/21);89SrCl2与唑来膦酸联合治疗组疼痛缓解总有效率为95.5%(21/22),病灶治疗有效率为54.5%(12/22),全身状况KPS评分提高率86.4%(19/22)。联合治疗组的疗效优于单项治疗组,差异有统计学意义(P<0.05)。血液毒性反应分别为19.0%和22.7%,差异无统计学意义(P>0.05)。结论89SrCl2联合唑来膦酸对转移性骨肿瘤有明显疗效,不良反应小,联合治疗效果优于单纯89SrCl2治疗。
Objective To investigate the clinical efficacy of strontium chloride (89SrCl2) and 89SrCl2 combined with zoledronic acid in the treatment of metastatic bone tumors. Methods Forty-three patients with metastatic bone tumors were divided into two groups randomly. Twenty-one patients were treated with 89SrCl2 alone and 22 patients were treated with 89SrCl2 and zoledronic acid. Observe the treatment of bone pain relief effect, the efficacy of metastatic lesions, quality of life and hematological toxicity. Data were subjected to χ2 test using SPSS 14.0 statistical software. Results The total effective rate of pain relief was 71.4% (15/21) in treatment group 89SrCl2, the effective rate of treatment was 33.3% (7/21), and the improvement rate of KPS in general condition was 57.1% (12/21). 89SrCl2 The total effective rate of pain relief was 95.5% (21/22) in combination with zoledronic acid group, 54.5% (12/22) in focal lesion treatment and 86.4% (19/22) in general condition KPS score. The combined treatment group was superior to the single treatment group, the difference was statistically significant (P <0.05). The hematological toxicity was 19.0% and 22.7%, respectively, with no significant difference (P> 0.05). Conclusion 89SrCl2 combined with zoledronic acid has obvious curative effect on metastatic bone tumor with little adverse reaction, and the combined treatment is superior to 89SrCl2 alone.